Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00966693 · MORE INFO

Limitations, agreements, and source contact

Lenalidomide, Thalidomide and Dexamethasone in Treating Participants With Relapsed or Refractory Multiple Myeloma · Source last updated 2020-11-04

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
pi Sponsor Employee
true
limitations And Caveats
description
No pharmaco-dynamic marker to support an effect of signaling downregulation in lenalidomide-refractory patients to corroborate low dose thalidomide (50-100 mg) with or without dexamethasone has a therapeutic benefit with lenalidomide.
point Of Contact
email
dmweber@mdanderson.org
organization
UT MD Anderson Cancer Center
phone
713-792-2860
title
Weber,Donna M.,M.D. / Lymphoma/Myeloma
Complete source fields
certain Agreement
pi Sponsor Employee
true
limitations And Caveats
description
No pharmaco-dynamic marker to support an effect of signaling downregulation in lenalidomide-refractory patients to corroborate low dose thalidomide (50-100 mg) with or without dexamethasone has a therapeutic benefit with lenalidomide.
point Of Contact
email
dmweber@mdanderson.org
organization
UT MD Anderson Cancer Center
phone
713-792-2860
title
Weber,Donna M.,M.D. / Lymphoma/Myeloma

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice